erlotinib hydrochloride has been researched along with rociletinib in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (rociletinib) | Trials (rociletinib) | Recent Studies (post-2010) (rociletinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 61 | 5 | 60 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | rociletinib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1682 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.1176 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.1057 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.072 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1176 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Chen, M; Kanteti, R; Li, Y; Oh, YT; Owonikoko, TK; Ramalingam, SS; Riehm, J; Salgia, R; Shi, P; Sun, SY; Yao, W; Yue, P; Zhang, G | 1 |
| Jiang, Y; Li, Z; Wan, S; Wu, X; Yan, R; Zhang, J | 1 |
1 review(s) available for erlotinib hydrochloride and rociletinib
| Article | Year |
|---|---|
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
2 other study(ies) available for erlotinib hydrochloride and rociletinib
| Article | Year |
|---|---|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Nude; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Topics: Acrylamides; Allosteric Regulation; Aniline Compounds; Benzeneacetamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2019 |